CLINICAL TRIAL

Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

Efficacy and Safety of COMP360 Psilocybin therapy in Anorexia Nervosa: a Proof-of-concept Study This study aims to explore the efficacy and safety of COMP360 25 mg as compared to COMP360 1 mg (control condition) administered with psychological support in participants with Anorexia Nervosa

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2024-12-03
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

COMPASS Pathways

Watch author

Topics and keywords

psilocybin Eating Disorders Safety Other Anorexia Nervosa Psilocybin COMP360 COMPLETED

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderClinicalTrials.gov · 2025-06-12 The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant DepressionClinicalTrials.gov · 2023-11-08 Effects of Psilocybin in Anorexia NervosaClinicalTrials.gov · 2023-05-05 Evaluation of Psilocybin in Anorexia Nervosa: Safety and EfficacyClinicalTrials.gov · 2022-07-24 A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating DisorderClinicalTrials.gov · 2024-11-18 PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study)ClinicalTrials.gov · 2024-11-05 Psilocybin as a Treatment for Anorexia Nervosa: A Pilot StudyClinicalTrials.gov · 2024-06-16 The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionClinicalTrials.gov · 2023-04-23